Previous 10 | Next 10 |
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update PR Newswire JERUSALEM , Aug. 26, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ulti...
Annovis Bio, Inc. (NYSE:ANVS) -53% after presenting Alzheimer's drug data at AAIC 2021. Atreca, Inc. (NASDAQ:BCEL) -29% after presents initial clinical data from Phase 1b trial of ATRC-101 in select advanced solid tumors. Citrix Systems, Inc. (NASDAQ:CTXS) -16% on Q2 ...
Gainers: Intrusion (INTZ) +65%.MOGU (MOGU) +40%.Oragenics (OGEN) +32%.BiondVax Pharmaceuticals (BVXV) +29%.Sintx Technologies (SINT) +23%.Dyadic International (DYAI) +21%.EyeGate Pharmaceuticals (EYEG) +19%.U.S. Physical Therapy (USPH) +18%.ObsEva SA (OBSV) +16%.Orbsat (OSAT) +15%.Losers: IRS...
BiondVax Announces First Quarter 2021 Financial Results and Provides Business Update PR Newswire JERUSALEM , June 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultim...
Biondvax Pharmaceuticals (BVXV): FY GAAP EPS of -$0.003.Cash and cash equivalents of $2.9MPress Release For further details see: Biondvax Pharmaceuticals reports FY results
BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update PR Newswire JERUSALEM , May 13, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufactu...
Letter from BiondVax's New CEO to Shareholders PR Newswire JERUSALEM , March 23, 2021 /PRNewswire/ -- Dear Shareholders, After many years of pharmaceutical leadership positions in the US and Europe , I jumped at the opportunity to retu...
BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering Total Gross Proceeds of Underwritten Offering Approximately $13.8 million PR Newswire JERUSALEM , Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. ...
NEW YORK, NY / ACCESSWIRE / February 3, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $12.1 Million Follow-On Offering for BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) About BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical compa...
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering PR Newswire JERUSALEM, Israel , Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimat...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...